Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 3;81(6):815–822. doi: 10.1136/annrheumdis-2021-221664

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

ACR-20 response and change in HAQ-DI score over time. Supporting values are shown in online supplemental table S4. (A) Time course of ACR-20 response through week 16. Response rates are reported in the intention-to-treat population (ie, all randomised patients) with non-responder imputation; patients who discontinued the trial early, started a prohibited treatment, were lost to follow-up or had no ACR assessments had outcomes imputed as non-responses. (B) Adjusted mean change from baseline in HAQ-DI score through week 16. Placebo, n=66; deucravacitinib 6 mg once a day, n=70; deucravacitinib 12 mg once a day, n=67. P values indicate a difference from placebo: *p<0.05, **p≤0.01, ***p≤0.001, adjusted for multiplicity at week 16 only. ACR, American College of Rheumatology; HAQ-DI, Health Assessment Questionnaire-Disability Index; QD, once a day.